TY - JOUR
T1 - An overview of the toxicities of checkpoint inhibitors in older patients with cancer
AU - Alkharabsheh, Omar
AU - Kannarkatt, Paul
AU - Kannarkatt, Joseph
AU - Karapetyan, Lilit
AU - Laird-Fick, Heather S.
AU - Al-Janadi, Anas
N1 - Funding Information:
Al-Janadi received research funding from Merck. There are no other conflicts of interest to disclose.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/9
Y1 - 2018/9
N2 - Checkpoint inhibitors offer an exciting new option for treatment of a wide variety of cancers. By binding to surface receptors or their associated ligands on T cells, this class of drugs enhances immune activation and response to cancer cells. In available studies, the drugs are well tolerated, although toxicity involving skin, gastrointestinal tract, liver, lungs, and endocrine organs has been observed. Unfortunately, few studies to date have included patients older than 70 years of age. Since aging has been linked to changes in immune function, there are theoretical concerns that this patient population might experience a different profile of adverse events. This article reviews the tolerability of checkpoint inhibitors in older patients with cancer in clinical practice.
AB - Checkpoint inhibitors offer an exciting new option for treatment of a wide variety of cancers. By binding to surface receptors or their associated ligands on T cells, this class of drugs enhances immune activation and response to cancer cells. In available studies, the drugs are well tolerated, although toxicity involving skin, gastrointestinal tract, liver, lungs, and endocrine organs has been observed. Unfortunately, few studies to date have included patients older than 70 years of age. Since aging has been linked to changes in immune function, there are theoretical concerns that this patient population might experience a different profile of adverse events. This article reviews the tolerability of checkpoint inhibitors in older patients with cancer in clinical practice.
KW - Elderly cancer patients
KW - Immune checkpoint inhibitors
KW - Immune-related adverse events
UR - http://www.scopus.com/inward/record.url?scp=85044161858&partnerID=8YFLogxK
U2 - 10.1016/j.jgo.2018.02.002
DO - 10.1016/j.jgo.2018.02.002
M3 - Review article
C2 - 29567089
AN - SCOPUS:85044161858
VL - 9
SP - 451
EP - 458
JO - Journal of Geriatric Oncology
JF - Journal of Geriatric Oncology
SN - 1879-4068
IS - 5
ER -